Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban : an international multicentre single-arm clinical trial
Barco, S., Schmidtmann, I., Ageno, W., Bauersachs, R. M., Becattini, C., Bernardi, E., Beyer-Westendorf, J., Bonacchini, L., Brachmann, J., Christ, M., Czihal, M., Duerschmied, D., Empen, K., Espinola-Klein, C., Ficker, J. H., Fonseca, C., Genth-Zotz, S., Jiménez, D., Harjola, V.-P., . . . Lankeit, M. (2020). Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban : an international multicentre single-arm clinical trial. European Heart Journal, 41(4), 509-518. https://doi.org/10.1093/eurheartj/ehz367
Julkaistu sarjassa
European Heart JournalTekijät
Päivämäärä
2020Tekijänoikeudet
© The Authors 2019. Published by Oxford University Press on behalf of the European Society of Cardiology
Aims:
To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Methods and results:
We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was symptomatic recurrent venous thromboembolism (VTE) or PE-related death within 3 months of enrolment. An interim analysis was planned after the first 525 patients, with prespecified early termination of the study if the null hypothesis could be rejected at the level of α = 0.004 (<6 primary outcome events). From May 2014 through June 2018, consecutive patients were enrolled in seven countries. Of the 525 patients included in the interim analysis, three (0.6%; one-sided upper 99.6% confidence interval 2.1%) suffered symptomatic non-fatal VTE recurrence, a number sufficiently low to fulfil the condition for early termination of the trial. Major bleeding occurred in 6 (1.2%) of the 519 patients comprising the safety population. There were two cancer-related deaths (0.4%).
Conclusion:
Early discharge and home treatment with rivaroxaban is effective and safe in carefully selected patients with acute low-risk PE. The results of the present trial support the selection of appropriate patients for ambulatory treatment of PE.
...
Julkaisija
Oxford University PressISSN Hae Julkaisufoorumista
0195-668XAsiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/34632357
Metadata
Näytä kaikki kuvailutiedotKokoelmat
Lisätietoja rahoituksesta
HoT-PE is an independent, investigator-initiated trial with an academic sponsor (Centre for Thrombosis and Haemostasis, University Medical Centre Mainz, Germany). The work of Stefano Barco, Philipp S. Wild, Stavros V. Konstantinides, and Mareike Lankeit was supported by the German Federal Ministry of Education and Research [BMBF 01EO1003 and 01EO1503]. In addition, the sponsor has obtained the study drug (rivaroxaban) and a grant from the market authorization holder of rivaroxaban, Bayer AG. ...Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Sports and exercise medicine clinic in public hospital settings : a real-life concept and experiences of the treatment of the first 1151 patients
Alanko, Lauri; Laukkanen, Jari A.; Rottensteiner, Mirva; Rasmus, Salla; Kuha, Tero; Valtonen, Maarit; Kujala, Urho M. (Taylor & Francis, 2023)Objective Physical exercise has been shown to have a variety of health-promoting effects, including improvements in cardiorespiratory and muscular fitness, symptoms and risk factors such as LDL and HDL cholesterol, ... -
Effectiveness of Distance Technology in Promoting Physical Activity in Cardiovascular Disease Rehabilitation : Cluster Randomized Controlled Trial, A Pilot Study
Hakala, Sanna; Kivistö, Heikki; Paajanen, Teemu; Kankainen, Annaliisa; Anttila, Marjo-Riitta; Heinonen, Ari; Sjögren, Tuulikki (JMIR Publications Inc., 2021)Background: Physical activity is beneficial for cardiovascular rehabilitation. Digitalization suggests using technology in the promotion of physical activity and lifestyle changes. The effectiveness of distance technology ... -
How was remote technology accepted among cardiac rehabilitees in outpatient self-rehabilitation context?
Säteri, Sanna; Heinonen, Ari; Sjögren, Tuulikki (Taylor & Francis, 2023)The purpose of the article The purpose of this study was to investigate cardiac rehabilitees’ experiences with wrist-worn activity monitor (Fitbit Charge HR) and internet-based coaching software (Movendos m-coach) in ... -
Effectiveness of peer support on health-related quality of life in recently diagnosed breast cancer patients : a randomized controlled trial
Toija, Anu; Kettunen, Tarja; Leidenius, Marjut; Vainiola, Tarja; Roine, Risto P. (Springer, 2019)Purpose: Breast cancer is the most common cancer of Finnish women. Peer support could be a way to help breast cancer patients to deal with the disease but studies on its effectiveness have produced conflicting results. ... -
Social Cognition Correlates of Self-Management Behaviors in Patients with Familial Hypercholesterolemia (FH) : A Meta-Analytic Review
Majeed, Rabia; Hamilton, Kyra; Watts, Gerald, F.; Hagger, Martin, S. (Elsevier, 2024)Objective Familial Hypercholesterolemia (FH) is an inherited disorder leading to increased risk of premature atherosclerotic cardiovascular disease. This risk can be ameliorated through adherence to pharmacological treatment ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.